Cargando…

Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei

Pseudomyxoma peritonei (PMP) is a rare mucinous disease most commonly arising from the appendix. Pleural involvement arising from established PMP is seen in a small number of cases. Combined cytoreductive surgery and hyperthermic intrathoracic chemotherapy is the treatment of choice when managing in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Anthony R., Bazzi, Khalil, Valle, Sarah J., Morris, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077436/
https://www.ncbi.nlm.nih.gov/pubmed/33976645
http://dx.doi.org/10.1159/000514273
_version_ 1783684883675086848
author Lam, Anthony R.
Bazzi, Khalil
Valle, Sarah J.
Morris, David L.
author_facet Lam, Anthony R.
Bazzi, Khalil
Valle, Sarah J.
Morris, David L.
author_sort Lam, Anthony R.
collection PubMed
description Pseudomyxoma peritonei (PMP) is a rare mucinous disease most commonly arising from the appendix. Pleural involvement arising from established PMP is seen in a small number of cases. Combined cytoreductive surgery and hyperthermic intrathoracic chemotherapy is the treatment of choice when managing intra-thoracic PMP. In cases of recurrence, surgical intervention may be technically challenging and carry higher rates of complications, morbidity, and mortality. Bromelain and acetylcysteine (BromAc<sup>®</sup>) is a novel treatment modality that has demonstrated mucolytic properties. When injected directly into mucinous disease, it facilitates tumour dissolution and allows it to be aspirated. It has recently been tested in the treatment of inoperable peritoneal mucinous disease, with an acceptable safety profile and positive objective response. Here we describe the first two cases of BromAc<sup>®</sup> administered directly into pleural adenomucinosis, with striking differences in response between the two patients likely due to differences in tumour hardness.
format Online
Article
Text
id pubmed-8077436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-80774362021-05-10 Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei Lam, Anthony R. Bazzi, Khalil Valle, Sarah J. Morris, David L. Case Rep Oncol Case Report Pseudomyxoma peritonei (PMP) is a rare mucinous disease most commonly arising from the appendix. Pleural involvement arising from established PMP is seen in a small number of cases. Combined cytoreductive surgery and hyperthermic intrathoracic chemotherapy is the treatment of choice when managing intra-thoracic PMP. In cases of recurrence, surgical intervention may be technically challenging and carry higher rates of complications, morbidity, and mortality. Bromelain and acetylcysteine (BromAc<sup>®</sup>) is a novel treatment modality that has demonstrated mucolytic properties. When injected directly into mucinous disease, it facilitates tumour dissolution and allows it to be aspirated. It has recently been tested in the treatment of inoperable peritoneal mucinous disease, with an acceptable safety profile and positive objective response. Here we describe the first two cases of BromAc<sup>®</sup> administered directly into pleural adenomucinosis, with striking differences in response between the two patients likely due to differences in tumour hardness. S. Karger AG 2021-03-31 /pmc/articles/PMC8077436/ /pubmed/33976645 http://dx.doi.org/10.1159/000514273 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Lam, Anthony R.
Bazzi, Khalil
Valle, Sarah J.
Morris, David L.
Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei
title Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei
title_full Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei
title_fullStr Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei
title_full_unstemmed Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei
title_short Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei
title_sort novel use of bromelain and acetylcysteine (bromac®) for pleural involvement in pseudomyxoma peritonei
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077436/
https://www.ncbi.nlm.nih.gov/pubmed/33976645
http://dx.doi.org/10.1159/000514273
work_keys_str_mv AT lamanthonyr noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei
AT bazzikhalil noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei
AT vallesarahj noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei
AT morrisdavidl noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei